InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

Core Viewpoint - InflaRx N.V. is implementing cost-reduction measures to extend its cash runway and focus resources on the development of izicopan, a potential best-in-class C5aR inhibitor for hidradenitis suppurativa (HS) and other inflammatory and immunological (I&I) indications [1][2]. Financial and Operational Restructuring - The company is streamlining its organizational structure and discontinuing non-essential activities outside the development of izicopan to improve capital efficiency [3]. - InflaRx is reducing its workforce by approximately 30% and significantly cutting spending related to Gohibic (vilobelimab), which will incur a one-time charge of about $7 million, primarily a non-cash charge for inventory write-off [4]. - These actions are expected to create a leaner cost structure, allowing for substantial reductions in operating expenses and extending the cash runway to mid-2027 [4]. Development Focus on Izicopan - InflaRx is prioritizing resources for izicopan, which has shown a favorable pharmacokinetic/pharmacodynamic profile and potential to address HS, chronic spontaneous urticaria (CSU), and other I&I indications [7]. - The company is in active discussions with the FDA regarding the Phase 2b study design for izicopan in HS, aiming to differentiate it from existing therapies [8]. - A PK bridging study in China is planned for 2026 to expedite proof of concept studies for izicopan in additional geographies [12]. Clinical Progress and Future Plans - InflaRx continues to make progress toward Phase 2b readiness for izicopan in HS and plans to present Phase 2a datasets for izicopan in HS and CSU at medical conferences later this year [11][10]. - The company intends to host a virtual Capital Markets Day in spring 2026 to showcase the clinical utility and commercial potential of izicopan [13]. Product Overview - Izicopan (INF904) is an orally administered small molecule inhibitor of the C5a receptor, demonstrating anti-inflammatory effects in pre-clinical and human studies, with a favorable safety profile and significant efficacy in reducing symptoms in HS and CSU patients [14][15].